In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

BMS, Novartis to co-promote tegaserod and develop compounds

Executive Summary

Bristol-Myers Squibb will co-develop and co-promote (except in Japan) Novartis's Zelmac (tegaserod) to treat irritable bowel syndrome. In return BMS will give Novartis certain rights to two of its drug candidates, CTLA 4Ig and LEA 29Y, in development to stop rejection of transplanted organs.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Co-Promotion
    • Product or Technology Swap
    • R&D and Marketing (Licensing)

Related Companies